Oncology
Owkin has spun out its diagnostics division as Waiv, raising $33m to scale AI precision testing in oncology. Waiv CEO Meriem Sefta tells Medtech Insight why the diagnostic infrastructure underpinning precision medicine is already broken – and how Waiv intends to fix it.
Curve Biosciences is developing a technology that analyzes signals from blood and organs to monitor the progression of chronic disease. The first product is a blood test to monitor patients with liver cirrhosis at risk for liver cancer, the second for MASH.
NVision is pursuing regulatory clearance in the US, with trials launching across the US, Europe and Asia. In Europe, it is starting with Germany, Denmark, the UK and Italy before seeking broader EMA approval.
The US Medicare agency is now covering superficial radiotherapy (SRT) for the treatment of skin cancer. Joseph Sardano, CEO of SRT firm Sensus Healthcare, spoke to Medtech Insight about the potential of the technology and why it’s still facing adaptation challenges.
New Precision IO Group CEO Kurt Azarbarzin outlines the near-term strategy for Quantum Surgical’s robotic-assisted ablation platform and NeuWave Medical’s microwave technology. Quantum recently acquired NeuWave, but the companies will continue to operate independently.
Grail reported full-year revenue of $147.2m, up 17% year-over-year. US Galleri revenue rose 26% from the prior year to $136.8m.
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
Novocure’s Optune Pax is a wearable non-invasive device that uses electrical fields to disrupt the growth of cancer cells. A pivotal trial showed longer survival in patients who used the device than in those treated with chemotherapy alone.
Molecular diagnostics firm SAGA Diagnostics has introduced a colorectal cancer test that can detect even very low levels of cancer biomarkers. The test helps clinicians guide post-surgical treatment decisions.
A pair of diagnostic developers backed with venture capital have teamed up with the University of Tennessee to fight colorectal cancer. The collaboration seeks to advance next generation testing to catch one of the deadliest cancers in its earliest stages.
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech funding in 2025 sees a trend of fewer, yet larger deals with total funding of $3.6bn in Q1, $2.6bn in Q2 and $2.9bn in Q3, said LSI’s Nick Talamantes. In 2026, he expects a continued investor focus on more mature firms in areas of oncology, cardiology and neurology.
Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.
A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.
Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.
Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test
Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.
Delfi Diagnostics is preparing for pivotal trial results that could support FDA approval and reimbursement for its fragmentomics-based lung cancer screening test. Early data suggest strong potential to improve screening uptake and expand access to early detection.
Inspired by his son’s battle with cancer, Neal Piper founded Luminoah to modernize enteral feeding. Its smart, pocket-sized pump tracks nutrition in real time to prevent malnutrition and improve quality of life for patients and caregivers.